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THE MENSTRUAL CYCLE
An understanding of the sequence of events that occur in a normal menstrual
cycle is necessary for the management of menstrual disturbances.  The hypothala-
mus secretes gonadotropin-releasing hormone (GnRH) in a pulsatile manner that
stimulates the pituitary to release follicle-stimulating hormone (FSH) and luteinis-
ing hormone (LH).  The co-ordination of these trophic hormones stimulates the
ovary to develop a cohort of follicles, selects the dominant Graafian follicle
which secretes oestrogen in the follicular phase, releases an oocyte in response
to the LH/FSH surge (ovulation) and then forms the corpus luteum that secretes
progesterone.  The lifespan of the corpus luteum is about 14 days if implantation
does not occur.  The ovarian steroid hormones (oestradiol and progesterone) pro-
vide feedback to the hypothalamus and pituitary to prepare for the next menstru-
al cycle.  Changes in any portion of the hypothalamic-pituitary-ovarian (HPO)
axis can lead to menstrual cycle disturbances.  
CAUSES OF ABNORMAL UTERINE BLEEDING
The causes of abnormal vaginal bleeding include gynaecological pathology
(30%), endocrine disorders (5%), haematological causes (5%), and in the majori-
ty of cases (60%)  there is no organic disease, and the bleeding is termed dys-
functional.  Menorrhagia is usually due to ovulatory dysfunctional uterine bleed-
ing (DUB), whereas oligomenorrhoea is due to anovulatory DUB which often
occurs at the extremes of reproductive age.  
Following clinical evaluation, the approach to management of menstrual distur-
bances depends on, among others, the age, reproductive wishes (fertility or con-
traception), and if the bleeding is secondary to contraceptive or hormonal thera-
py.  In sexually active women presenting with menstrual aberrations, pregnancy
complications must be excluded.
I shall approach the management of these women in the context of their clinical
presentation:
• the adolescent presenting with irregular menses
• abnormal bleeding on hormonal contraception
• bleeding in the perimenopausal years
• postmenopausal bleeding.
ABNORMAL UTERINE BLEEDING DURING ADOLESCENCE
Adolescents with menstrual problems usually present with irregular cycles and
heavy periods.  Although a few patients do have an organic lesion that causes
abnormal bleeding, most suffer from DUB, which is defined as abnormal bleed-
ing for which no cause is found.  In 95% of cases of DUB, the slow maturation of
the HPO axis leads to anovulatory cycles.  The physiological abnormality is the
lack of a positive feedback mechanism necessary to initiate a LH surge and sub-
sequent ovulation.  Anovulation results in continuous oestrogen production with-
out progesterone, producing a thick, unstable and fragile endometrium that out-
grows its blood supply; sloughing occurs in a disordered fashion and produces
breakthrough bleeding, resulting in excessive blood loss leading to anaemia.  A
minority of adolescents will present with regular, heavy periods (ovulatory DUB)
due to a prostaglandin imbalance and excessive fibrinolytic activity in the
endometrium.
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MENSTRUAL DISTURBANCES
Abnormal uterine bleeding may either be excessively heavy regular menstrual periods
or irregular bleeding. 
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In the sexually active adolescent, preg-
nancy and its complications, and
bleeding resulting from hormonal con-
traception, must be excluded.  Those
who present at menarche or soon after
with an acute bleeding episode result-
ing in anaemia (haemoglobin 
< 10 g/dl) must be evaluated for a
bleeding disorder, endocrine disorders
and systemic illnesses.  In the non-sex-
ually active adolescent, pelvic exami-
nation should be replaced by abdomi-
nal palpation, vulval inspection and
non-invasive pelvic ultrasound exami-
nation.
Once a diagnosis of DUB is made, a
simple explanation of the physiology
of menses should be given together
with reassurance regarding functional
and anatomical normality of the geni-
tal tract.  Many cases of DUB resolve
spontaneously and no specific treat-
ment is required.  
Assessing menstrual flow objectively is
difficult and is best assessed by meas-
uring haemoglobin (Hb) levels.  If the
Hb level is > 12 g/dl, reassurance
and explanation are necessary with a
review at 6-monthly intervals.  The use
of a menstrual calendar will help in
assessing improvement.  The majority
of cases will resolve within 1 - 2 years
with the onset of spontaneous ovula-
tion.  
A patient with an Hb value of 
< 12 g/dl should be offered iron sup-
plementation and hormonal treatment
to regulate the menses.  Cyclical
progestogen therapy (Provera or
Primolut N) for 10 days a month or
the low-dose combined oral contracep-
tive (COC) pill will help regularise her
menstrual cycle. Many parents of
younger adolescents are reluctant to
encourage the use of the COC; in
these cases it is advisable to use
progestogens. If there is associated
dysmenorrhoea (ovulatory DUB),
prostaglandin synthetase inhibitors
(mefenamic acid) are prescribed dur-
ing menses.  
Patients presenting with acute profuse
bleeding and/or hypotension require
emergency management.  Fluid resus-
citation and blood transfusion may be
required.  Immediate management
with hormone therapy is also indicat-
ed.  Haemorrhage may be arrested by
large oral doses of progestogen or
high doses of oestrogen followed by a
progestogen-dominant COC (Ovral).
Patients unable to take oral medica-
tions may be given intravenous
Premarin 25 mg every 4 - 6 hours for
a maximum of 6 doses.  Progestogens,
either oral or intramuscular Depo
Provera, must follow intravenous
oestrogen to stabilise the endometri-
um.  Once bleeding is under control,
Ovral should be given 3 times a day
for 2 - 3 days and then a single pill
daily to complete 21 days of therapy.
Large doses of oestrogen may cause
vomiting and an anti-emetic may also
be required.  A withdrawal bleed will
then occur and Ovral or a lower-dose
monophasic pill (Nordette) may be
continued for at least 6 months or until
iron stores return to normal.  Any
relapse may be treated with progesto-
gen as described above.  Dilatation
and curettage (D & C) should be





Bleeding problems are among the
most common reasons for unsuccessful
use and discontinuation of hormonal
contraception.  Intermenstrual or
breakthrough bleeding and spotting
occur in approximately 25% of women
during the first 3 months of the COC,
but become less common with ongoing
use.  Bleeding on contraceptives rarely
signifies major pathology in pre-
menopausal women, although it may
alarm women.  Nevertheless it is still
important to take a detailed history
and examination to exclude other
causes of abnormal bleeding.  
Combined oral
contraceptives (COC)
The management of intermenstrual
bleeding on COCs begins with coun-
selling prior to prescription of the
COC.  Ensure that the woman is not
smoking and that compliance is good.
Cigarette smoking is associated with
anti-oestrogenic effects and may lower
oestrogen levels. If bleeding occurs in
the first 3 months, reassurance and
encouragement is all that is needed.
If bleeding occurs after 3 months and
if other causes including pregnancy
are excluded, treatment with supple-
mental oestrogen and/or a non-
steroidal anti-inflammatory drug
(NSAID) will stop the bleeding.
Supplemental oestrogen (Premarin
0.625 mg or Estinyl 20 µg daily for 1
week) will increase endometrial thick-
ness and stabilise the endometrium
and blood vessels.  If the bleeding
persists, try another COC containing a
different progestogen.  
Progestogen-only pill (POP)
Menstrual aberrations may occur in
more than 50% of women.  As POP
are short-acting (up to 20 hours) timely
ingestion is important.  The POP
should be taken at the same time
every day as a variability of 2 - 3
hours can cause menstrual distur-
bances.  In women having prolonged
bleeding, 1 POP taken twice daily for
7 - 10 days should control the bleed-
ing.  Repeat the course once if bleed-
ing continues.  Discontinue this method
if bleeding still persists and switch to a
COC pill if this is not contraindicated.
Supplemental oestrogen must not be
used as this may impair the cervical
mucus effect and reduce the effect of
the POP.  If there has been amenor-
rhoea followed by bleeding, an
ectopic pregnancy or miscarriage must
be excluded.
Injectable progestogens
Unpredictable bleeding occurs in 70%
of women using injectable contracep-
tion.  Regular cycles may disappear
and are replaced by the occurrence of
erratic spotting, intermittent bleeding
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es (5%), and in the majori-
ty of cases (60%) there is
no organic disease, and
the bleeding is termed dys-
functional.
Assessing menstrual flow
objectively is difficult and
is best assessed by measur-
ing haemoglobin (Hb) lev-
els.
Bleeding problems are
among the most common
reasons for unsuccessful
use and discontinuation of
hormonal contraception.
or a brown discharge following the
first one or two injections.  With con-
tinued use, this decreases and
oligomenorrhoea or amenorrhoea
develops.  
Counselling prepares women for both
initial irregular spotting and the latter
development of amenorrhoea.  In the
treatment of prolonged spotting which
occurs in the first 6 weeks after the
first or second injection, it is important
to reassure the woman that her bleed-
ing is not due to cancer but to
endometrial atrophy and she will soon
become amenorrhoeic.  Antiprosta-
glandins and tranexamic acid may be
prescribed.  A course of oestrogen (1 -
3 weeks) and iron supplements may
be given to women who insist on a
therapeutic intervention.  If the bleed-
ing is heavy and prolonged, examina-
tion must exclude pregnancy complica-
tions, fibroids, infection and polyps.
In the absence of pathology, high-dose
oestrogen (Premarin 1.25 -2.5 mg or
Ovral) for up to 21 days may be used
for heavy bleeding.  A withdrawal
bleed will occur after cessation of
either of these regimens.  The course
may be repeated if this withdrawal
bleed lasts for more than a week.
If bleeding occurs in the latter half of
the injection cycle, the subsequent
injection may be administered.
Bleeding should stop within a week
and the next routine injection can fol-
low. Bleeding after the third injection
can be treated with oestrogen, as
already described.  If bleeding per-
sists, the regimen may be repeated
once and if it still persists another




Endometrial cancer is predominantly a
disease of postmenopausal women;
however 5% of patients present with
irregular menses before the
menopause.  This together with
endometrial hyperplasia are the two
most important conditions that need to
be excluded in women > 40 years old
with abnormal uterine bleeding.
Intermenstrual and postcoital bleeding
may be of common aetiology.  A cer-
vical ectropion, cervical cancer, cer-
vicitis, submucous fibroids and
endometrial/cervical polyps may
cause bleeding and therefore warrant
exclusion.  Dysfunctional bleeding is
also common towards the menopausal
years.
In the evaluation, a complete history
and examination is mandatory and
should include a Papanicolaou smear
and a pelvic ultrasound, if necessary.  
Women with regular, heavy menses
and a normal general and pelvic
examination may be empirically man-
aged as DUB.  Medical interventions
include the use of antifibrinolytics,
antiprostaglandins and COCs.  In
most situations, if there is failure of
medical therapy, inpatient hys-
teroscopy and surgery is performed.
The only therapeutic role for D & C is
in cases of continuous profuse bleed-
ing not responding to other therapeu-
tic modalities (this is very uncommon).
Histological examination of an
endometrial biopsy obtained either
with the pipelle or at the time of hys-
teroscopy and curettage is the method 




reduces menstrual loss by 35 - 55% by
its antifibrinolytic action.  NSAIDs
reduce endometrial prostaglandins,
thereby reducing pain and blood loss
by approximately 25%.  
The COC pill induces regular shed-
ding of a suppressed endometrium
and may reduce menstrual blood loss
by 50%.  In normotensive women who
do not smoke and do not have risk
factors for thrombosis, the low-dose
COC (< 35 µg) can be used until
menopause.  In perimenopausal
women with anovulatory cycles, COCs
not only reduce blood loss and the
need for surgical intervention, but also
alleviate vasomotor symptoms.
Cyclical progestogen therapy may
also co-ordinate regular shedding of
the endometrium in anovulatory
women.  It is ineffective in ovulatory
women unless used in high doses for
prolonged periods.  This is however
not a viable strategy as the side-
effects  of nausea, weight gain,
fatigue, mood changes, headaches,
depression and loss of libido are
unacceptable to women.  
The levonorgestrel intrauterine system
(Mirena) reduces menstrual blood loss
by 86% after 3 months and 97% after
12 months of use.  Thirty-five per cent
of women who use Mirena become
amenorrhoeic after 1 year.  This
method is an alternative to hysterecto-
my and should be offered before any
surgical option.  
Surgical treatment
Conservative surgery (retaining the
uterus) by ablating the endometrium is
offered following failed medical thera-
py and in women who have complet-
ed their families. Ablation techniques
include laser ablation, resection,
cryosurgery and microwaves.  The use
of Mirena and endometrial ablation is
likely to dramatically reduce the need
for hysterectomy in cases of DUB. 




The risk of endometrial carcinoma in
PMB increases with age from about
1% at 50 years to 25% at 80 years of
age.  In developing countries, carcino-
ma of the cervix is the leading malig-
nant cause of PMB.  The majority of
women with PMB have a benign cause
for their bleeding, the commonest
being genital tract atrophy.  Polyps
and endometrial hyperplasia are other
possible causes.  Following history,
examination and a cervical smear, the
traditional management was a D & C.
This procedure sampled less than 50%
of the endometrium and missed up to
10% of endometrial pathology and
15% of endometrial cancers.  Recent
advances using transvaginal ultra-
sound, outpatient endometrial biopsy
(Pipelle) and hysteroscopy either alone
or in combination have become the
methods of choice in the assessment of
PMB.  Cervical visualisation and cytol-
ogy must be performed in all PMB
cases, irrespective of when last per-
formed.  
Atrophic endometritis may be treated
with a short course of vaginal or sys-
temic oestrogen as long as its use is
not contraindicated.  Progestogen ther-
apy may be used in women with sim-
ple hyperplasia who are not fit for sur-
gery.  Basically, treatment is that of the
underlying pathology.
CONCLUSION
Menstrual disturbances are among the
commonest reasons for women visiting
their general practitioners.  An under-
standing of the endocrinology of the
menstrual cycle and the influence of
exogenous hormones is crucial in the
counselling and management strate-
gies of the various clinical presenta-
tions.
The major cause of abnormal uterine bleeding is dysfunctional uterine bleeding (DUB).
In sexually active women presenting with menstrual aberrations, pregnancy complications must be excluded.
Simple explanation and reassurance should be given to adolescents with DUB regarding the functional and anatomical
normality of the genital tract.
Breakthrough bleeding and spotting occur in 25% of women during the first 3 months of the oral contraceptive pill, but
improves with ongoing use.
The progestogen-only pill should be taken at the same time every day as a variability of 2 - 3 hours can cause menstrual
disturbances.
Endometrial cancer and hyperplasia are the two most important conditions that need to be excluded in perimenopausal
women with abnormal uterine bleeding and a normal cervical smear.
Tranexamic acid and prostaglandin synthetase inhibitors reduce menstrual loss by 35 - 55%.
Hysteroscopy and biopsy is preferable to dilatation and curretage (D & C) as the latter is a blind procedure that samples
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